No Data
No Data
No Data
No Data
No Data
Express News | Alkermes Expects To Initiate Vibrance-2 Phase 2 Study In Narcolepsy Type 2 In 2H 2024
Moomoo 24/7Apr 24 07:05 ET
Express News | Alkermes Initiates Vibrance-1 Phase 2 Study Of ALKS 2680 For Narcolepsy Type 1
Moomoo 24/7Apr 24 07:04 ET
Express News | Alkermes PLC: Expects to Initiate Vibrance-2, a Planned Phase 2 Study in Patients With Narcolepsy Type 2, in Second Half of 2024
Moomoo 24/7Apr 24 07:00 ET
Express News | Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating Alks 2680 for the Treatment of Narcolepsy Type 1
Moomoo 24/7Apr 24 07:00 ET
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared
AlkermesApr 24 00:00 ET
Alkermes (NASDAQ:ALKS) Shareholders Have Endured a 20% Loss From Investing in the Stock a Year Ago
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That
Simply Wall StApr 23 13:50 ET
Lionnell : small sell orders through $16.40
Lionnell : won't stay green
Simon backy : https://www.etfdailynews.com/2022/04/28/vaxxinity-inc-nasdaqvaxx-insider-mei-mei-hu-buys-8038-shares/
No Data
No Data